Carboplatin

From Citizendium, the Citizens' Compendium
Jump to: navigation, search
This article is developing and not approved.
Main Article
Talk
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and not meant to be cited; by editing it you can help to improve it towards a future approved, citable version. These unapproved articles are subject to a disclaimer.

In oncology, carboplatin is a antineoplastic agent that is an "organoplatinum compound that possesses antineoplastic activity."[1] As compared to cisplatin, carboplatin has equal (lung cancer, ovarian cancer) or less (germ cell tumors, bladder cancer, head and neck cancer) efficacy but less drug toxicity.[2] When considered in veterinary oncology, carboplatin can be used in cats but cisplatin is fatal to felines.

Carboplatin was developed specifically to reduce the toxicity of cisplatin. Both are members of what the World Health Organization calls "other neoplastic agents", specifically class L01XA. [3]

History

In the United States, it was approved with a New Drug Application (NDA) by the FDA in 1989.[4] A generic version was approved with a Abbreviated New Drug Application (ANDA) in 2003.[5]

Indications

Human

In the U.S., it is only approved for ovarian carcinoma, but common off-label uses include:[6]

Veterinary

It is usually the second chemotherapeutic agent used in feline squamous cell carcinoma.

Dosage

Carboplatin may be dosed by the Calvert formula:[7]

External links

The most up-to-date information about Carboplatin and other drugs can be found at the following sites.


References

  1. Anonymous (2015), Carboplatin (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Lokich J, Anderson N (1998). "Carboplatin versus cisplatin in solid tumors: an analysis of the literature.". Ann Oncol 9 (1): 13-21. PMID 9541678.
  3. WHO drug database search tool, [1]
  4. Drugs@FDA. U S Food and Drug Administration
  5. Drugs@FDA. U S Food and Drug Administration
  6. Carboplatin, American Society of Health System Pharmacists
  7. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. (1989). "Carboplatin dosage: prospective evaluation of a simple formula based on renal function.". J Clin Oncol 7 (11): 1748-56. PMID 2681557.